Why pharma disputes are uniquely demanding
Pharmaceutical and life-sciences litigation combines complex science with dense regulation and high stakes. A claim can turn on the design of a clinical trial, the adequacy of a drug's safety monitoring, a manufacturing deviation, or the way a product was approved and labelled. In each, the evidence is technical and the audience, eventually, includes experts on the other side. A report that overstates or misreads the science will not survive.
Clinical trials and drug safety
Clinical trial disputes ask whether a study was properly designed, conducted and reported, judged against ICH Good Clinical Practice. Pharmacovigilance and drug-safety matters ask a sharper question: what was known about a risk, when, and whether the safety signal was acted on and reflected in the labelling. These cases reward an expert who can reconstruct the safety record and explain causation honestly.
Manufacturing, quality and regulation
GMP manufacturing disputes turn on Good Manufacturing Practice and the integrity of quality systems: deviations, batch release, contamination and recall. Regulatory questions require fluency in the frameworks of the MHRA, the European Medicines Agency and the US FDA, since approval, variation and promotion are all governed by them.
Patents and instructing the right expert
Where the dispute is about innovation rather than safety, pharmaceutical patents and freedom-to-operate require an expert who can provide the technical foundation for infringement and validity. Across all of these, the expert owes an overriding duty to the court under CPR Part 35. Our guide on how to instruct an expert witness explains the process.